Abstract
To acquire information on signal alteration corresponding to the changes in metastatic potential, we analysed protein tyrosine phosphorylation of low- and high-metastatic human osteosarcoma HuO9 sublines, which were recently established as the first metastatic model of human osteosarcoma. Tyrosine phosphorylation of proteins around 60, 70, and 120–130 kDa was enhanced in high-metastatic sublines. Among these proteins, the protein around 70 kDa, which was most remarkably phosphorylated, was identified as paxillin, a scaffold protein in integrin signaling. Activity of Src family kinase correlated well with metastatic potential, and a Src family kinase inhibitor, PP2, not only abolished tyrosine phosphorylation of paxillin but also impaired the motility of high-metastatic sublines. The expression of paxillin was also elevated in high-metastatic sublines, and knocking down of paxillin expression by RNAi method resulted in attenuated motility of high-metastatic cells. We also demonstrated that the phosphorylated form of paxillin is essential for the migration-promoting effect in human osteosarcoma. These findings suggest that enhanced activity of Src family kinases and overexpression of paxillin synergistically contribute to the high metastatic potential of human osteosarcoma through the hyperphosphorylation of paxillin.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- BSA:
-
bovine serum albumin
- Cas:
-
Crk-associated substrate
- FAK:
-
focal adhesion kinase
- FBS:
-
fetal bovine serum
- PBS:
-
phosphate-buffered saline
- PP2:
-
4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine
- PP3:
-
4-amino-7-phenylpyrazol [3,4-d]pyrimidine
- RNAi:
-
RNA interference
- SH2:
-
Src homology 2 domain
- siRNA:
-
short interfering RNA
References
Batanian JR, Cavalli LR, Aldosari NM, Ma E, Sotelo-Avila C, Ramos MB, Rone JD, Thorpe CM and Haddad BR . (2002). Mol. Pathol., 55, 389–393.
Burnham MR, Bruce-Staskal PJ, Harte MT, Weidow CL, Ma A, Weed SA and Bouton AH . (2000). Mol. Cell. Biol., 20, 5865–5878.
Burridge K, Turner CE and Romer LH . (1992). J. Cell. Biol., 119, 893–903.
Huang J, Asawa T, Takato T and Sakai R . (2003). J. Biol. Chem., 278, 48367–48376.
Huth JF and Eilber FR . (1989). Arch. Surg., 124, 122–126.
Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T and Mukai K . (2003). Clin. Exp. Metast., 20, 525–529.
Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P and Helman L . (2001). Cancer Res., 61, 3750–3759.
Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ . (2004). Nat. Med., 10, 182–186.
Kimura K, Nakano T, Park YB, Tani M, Tsuda H, Beppu Y, Moriya H and Yokota J . (2002). Clin. Exp. Metast., 19, 477–485.
Kiyokawa E, Hashimoto Y, Kobayashi S, Sugimura H, Kurata T and Matsuda M . (1998). Genes Dev., 12, 3331–3336.
Klinghoffer RA, Sachsenmaier C, Cooper JA and Soriano P . (1999). EMBO J., 18, 2459–2471.
Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos AG, Meyers PA, Healy JH, Gorlick R and Rao PH . (2004). Genes Chromosomes Cancer, 39, 11–21.
Lewis JM and Schwartz MA . (1998). J. Biol. Chem., 273, 14225–14230.
Marchetti D, Parikh N, Sudol M and Gallick GE . (1998). Oncogene, 16, 3253–3260.
Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M and LaQuaglia M . (1993). J. Clin. Oncol., 11, 449–453.
Nakamoto T, Sakai R, Ozawa K, Yazaki Y and Hirai H . (1996). J. Biol. Chem., 271, 8959–8965.
Nakano T, Tani M, Ishibashi Y, Kimura K, Park YB, Imaizumi N, Tsuda H, Aoyagi K, Sasaki H, Ohwada S and Yokota J . (2003). Clin. Exp. Metast., 20, 665–674.
Pawson T . (2004). Cell, 116, 191–203.
Petit V, Boyer B, Lentz D, Turner CE, Thiery JP and Valles AM . (2000). J. Cell. Biol., 148, 957–970.
Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, Yazaki Y and Hirai H . (1994). EMBO J., 13, 3748–3756.
Schaller MD . (2001). Oncogene, 20, 6459–6472.
Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR and Parsons JT . (1994). Mol. Cell. Biol., 14, 1680–1688.
Schaller MD and Parsons JT . (1995). Mol. Cell. Biol., 15, 2635–2645.
Schlaepfer DD, Broome MA and Hunter T . (1997). Mol. Cell. Biol., 17, 1702–1713.
Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, Moldovan L and Zielenska M . (2003). Genes Chromosomes Cancer, 38, 215–225.
Talamonti MS, Roh MS, Curley SA and Gallick GE . (1993). J. Clin. Invest., 91, 53–60.
Tsubouchi A, Sakakura J, Yagi R, Mazaki Y, Schaefer E, Yano H and Sabe H . (2002). J. Cell. Biol., 159, 673–683.
Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, Asada N, Abe S, Isu K, Sugita T and Tomita K . (2002). J. Clin. Oncol., 20, 3470–3477.
Turner CE . (2000). Nat. Cell. Biol., 2, E231–E236.
Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC, Eilber FR and Eckardt JJ . (1994). J. Clin. Oncol., 12, 1849–1858.
Yano H, Uchida H, Iwasaki T, Mukai M, Akedo H, Nakamura K, Hashimoto S and Sabe H . (2000). Proc. Natl. Acad. Sci. USA, 97, 9076–9081.
Yeatman TJ . (2004). Nat. Rev. Cancer, 4, 470–480.
Acknowledgements
We are grateful to Dr Y Sawada (Department of Biological Sciences, Columbia University) for donating paxillin cDNA. KA is an awardee of the Research Resident Fellowship from the Foundation for Promoting of Cancer Research (Japan) for the 3rd Term Comprehensive 10-Year-Strategy for Cancer Control. This study was supported by the Program for Promotion of Fundamental Studies in Health Science of Pharmaceuticals and Medical Devices Agency (PMDA).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Azuma, K., Tanaka, M., Uekita, T. et al. Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 24, 4754–4764 (2005). https://doi.org/10.1038/sj.onc.1208654
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208654
Keywords
This article is cited by
-
Extracellular vesicles released from ganglioside GD2-expressing melanoma cells enhance the malignant properties of GD2-negative melanomas
Scientific Reports (2023)
-
Signaling domains of cancer-associated glycolipids
Glycoconjugate Journal (2022)
-
Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion
BMC Cancer (2017)
-
Knockdown of WAVE3 impairs HGF induced migration and invasion of prostate cancer cells
Cancer Cell International (2015)
-
Meta-analysis of differentially expressed genes in osteosarcoma based on gene expression data
BMC Medical Genetics (2014)